Rinvoq Patient Assistance Program Guide

——————————————————————————–

Rinvoq (upadacitinib) is an oral JAK inhibitor made by AbbVie and approved by the FDA for a growing list of inflammatory conditions — including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, giant cell arteritis, ulcerative colitis, Crohn’s disease, atopic dermatitis, and certain juvenile arthritis. Its retail price often exceeds $6,000 per month, placing it out of reach for many people paying without help. The Rinvoq Patient Assistance program — run by AbbVie through myAbbVie Assist and the AbbVie Patient Assistance Foundation — can provide the medication at no cost to patients who meet financial and coverage criteria, while a separate savings card helps many commercially insured patients. This guide explains how each path generally works. Program terms and income limits change, so treat the figures here as a starting point and verify current criteria with AbbVie.

Free Market Healthcare is an independent educational resource and is not affiliated with, endorsed by, or sponsored by AbbVie. We describe these programs for educational purposes; the official source is AbbVie, and treatment decisions belong with your prescriber.

Two Different Savings Paths — Start Here

Which program fits you depends almost entirely on your insurance:

• No insurance, or insurance that does not cover Rinvoq: the patient assistance program (PAP) through myAbbVie Assist may supply the drug free if you qualify by income.
• Commercial or employer insurance that does cover Rinvoq: the Rinvoq Complete Savings Card can cut your monthly out-of-pocket cost dramatically — eligible patients may pay as little as $0 a month.
• Medicare, Medicaid, VA, or Tricare: you cannot use the manufacturer savings card, but you may qualify for Medicare’s Extra Help or nonprofit copay foundations (details below).

What the Rinvoq Patient Assistance Program Covers

The Rinvoq Patient Assistance program provides Rinvoq tablets (available in strengths such as 15 mg, 30 mg, and 45 mg) at no cost to qualifying patients, across its FDA-approved indications. Whether Rinvoq is prescribed for rheumatoid arthritis, atopic dermatitis, an inflammatory bowel condition, or another approved use, you apply through the same myAbbVie Assist pathway.

Approved patients typically receive a regular supply shipped to their home or their prescriber’s office. Enrollment generally lasts up to a year, with renewal required to continue. The program also connects patients with a support team that helps with insurance navigation, prior-authorization support, and general questions — part of the broader Rinvoq Complete support offering.

Eligibility Criteria (Verify Current Details)

To qualify for the PAP, patients generally must meet all of the following, though AbbVie sets the exact, current rules:

• Residency and prescription: be a U.S. resident with a valid Rinvoq prescription from a licensed provider.
• Coverage status: lack insurance that pays for Rinvoq — meaning no Medicare Part D, Medicaid, VA, Tricare, or commercial coverage that covers the drug (the underinsured are sometimes considered case-by-case).
• Income: have household income at or below AbbVie’s threshold for the product.

AbbVie sets income limits as specific dollar amounts by household size, and for its specialty products these have generally fallen in the range of about 400% to 600% of the federal poverty level. Using the 2026 federal poverty guidelines (individual $15,960; family of four $33,000), 400% is roughly $63,840 for one person and about $132,000 for a family of four, and 600% for one person is roughly $95,760. Treat these as illustrative only — AbbVie can change its cutoffs, and it may consider documented financial hardship on a case-by-case basis, so verify the current income limit with AbbVie before assuming you do or do not qualify.

Step-by-Step Application Process

The application involves your prescriber. Your provider obtains the myAbbVie Assist enrollment form from the Rinvoq Complete resources or by calling 1-800-222-6885 (1-800-2myABBV). The prescriber section captures your diagnosis, prescribed dose, and medical rationale for Rinvoq.

You complete the patient section — household income, insurance status, and contact information — and attach proof of income, such as your most recent federal tax return (Form 1040), recent pay stubs, or a Social Security benefits statement, plus a copy of a government-issued photo ID. Your prescriber submits the completed package. Processing commonly takes a few weeks; ask your prescriber about bridge supply or expedited review if you need Rinvoq before approval. Because forms and timelines change, confirm the current requirements when you start.

Rinvoq Savings for Insured Patients

If you have commercial or employer insurance that covers Rinvoq but your out-of-pocket cost is high, the Rinvoq Complete Savings Card can lower your copay substantially — AbbVie’s current messaging is that eligible patients may pay as little as $0 a month. The card has an annual maximum benefit that varies by program year, and it is available only to patients with private or employer-sponsored insurance. Confirm the current terms, maximum, and eligibility when you enroll.

Patients with government insurance (Medicare Part D, Medicaid, Tricare, VA) cannot use manufacturer copay cards. Medicare beneficiaries should explore Medicare Extra Help to reduce Part D costs, and note that Medicare’s Part D out-of-pocket spending is now capped annually under recent reforms. Nonprofit copay foundations — such as the PAN Foundation and the HealthWell Foundation — may also offer grants for Medicare patients taking JAK inhibitors when funding is open.

Rinvoq Within the AbbVie Patient Assistance Ecosystem

The Rinvoq PAP is part of the broader AbbVie Patient Assistance program (myAbbVie Assist). If you take other AbbVie medicines — such as Skyrizi or Venclexta — you can pursue assistance for multiple drugs through the same overarching process, which can streamline paperwork. AbbVie’s support infrastructure also includes nurse-ambassador guidance for patients starting Rinvoq, covering practical questions about oral dosing, potential side effects, and coordinating Rinvoq with other treatments; this support is generally available regardless of how you pay.

Understanding Rinvoq’s Role — and Its Boxed Warnings

Rinvoq is typically prescribed after conventional therapies (such as methotrexate) or biologic DMARDs have been tried. As an oral JAK inhibitor it offers convenience over injectable biologics, and clinical trials have shown meaningful improvements versus placebo and active comparators across its indications. But the choice to use it is a clinical one made with your prescriber.

Importantly, the FDA has issued boxed warnings for JAK inhibitors, including Rinvoq, covering serious infections, increased risk of death (in certain older patients with cardiovascular risk factors), cancer (including lymphoma), major adverse cardiovascular events, and blood clots. These warnings are why Rinvoq is prescriber-directed and requires ongoing monitoring and follow-up. A patient assistance program changes only how you pay — it does not change the need for careful medical supervision, and it is not a substitute for discussing risks and benefits with your clinician.

Alternative Savings Paths

If the Rinvoq PAP is not available to you, other options may help. 340B pharmacies at qualifying hospitals and health centers may dispense Rinvoq at reduced cost. Prescription discount cards offer more modest savings on specialty drugs. State Pharmaceutical Assistance Programs can supplement Medicare Part D for eligible residents. For commercially insured patients facing high deductibles or coinsurance, the manufacturer savings card is usually the most impactful option; for uninsured patients, the PAP is typically the best path. Compare all available options and see our healthcare costs guide for a strategic approach across your full medication list.

Frequently Asked Questions

Can I use Rinvoq Patient Assistance if I have Medicare?

Medicare Part D enrollees are generally ineligible for the manufacturer PAP and cannot use the copay savings card. If you have Medicare but lack Part D or Medicare Advantage drug coverage, contact myAbbVie Assist at 1-800-222-6885 to discuss eligibility. Medicare patients should also explore Extra Help Medicare and nonprofit copay foundations. Verify current rules, since they change.

How long does approval take?

Processing commonly takes a few weeks. Expedited review may be available for urgent clinical needs — your prescriber can call Rinvoq Complete to request faster handling and ask about a bridge supply.

What if my insurance denies coverage for Rinvoq?

AbbVie’s Rinvoq Complete team can help with the appeals process, including letters of medical necessity and prior-authorization support. If a denial is upheld and you are effectively uninsured for Rinvoq, you may then qualify for the PAP.

Is there a generic version of Rinvoq?

As of 2026, there is no generic upadacitinib available in the United States; Rinvoq is protected by patents. When generics eventually enter the market, prices are expected to fall.

Can I pick up Rinvoq at my local pharmacy through the PAP?

Rinvoq supplied through the PAP is typically shipped by a specialty pharmacy to your home or prescriber’s office rather than dispensed at a retail counter. The savings card program for commercially insured patients works at participating pharmacies. Confirm the current fulfillment process when you enroll.

Start Your Application

Inflammatory conditions need consistent treatment to prevent flares and long-term damage, and cost should not be the barrier. If you are uninsured or underinsured, ask your prescriber to help you apply to myAbbVie Assist; if you have commercial insurance, ask about the Rinvoq Complete Savings Card. You can also call 1-800-222-6885 for direct support. Always confirm the current eligibility rules, income limits, and program terms, since they change — and keep your Rinvoq decisions, including monitoring, in the hands of your prescriber. For more strategies, explore our healthcare costs guide.

Sources

• AbbVie / RINVOQ — RINVOQ.com and Rinvoq Complete / myAbbVie Assist: covered indications, boxed warning, patient-support and savings-card program (“as little as $0”), and 1-800-222-6885.
• AbbVie — myAbbVie Assist / AbbVie Patient Assistance Foundation eligibility framework (U.S. residency, no coverage for the drug, income limits by household size).
• HHS (ASPE) — 2026 federal poverty guidelines (individual $15,960; family of four $33,000) used to frame income thresholds.
• CMS / Medicare.gov — Part D Low-Income Subsidy (Extra Help); manufacturer copay cards are not usable with government insurance; annual Part D out-of-pocket cap.
• FDA — JAK inhibitor class boxed warnings: serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis.